SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

GATTEX/REVESTIVE

TAK·TAKEDA PHARMACEUTICAL CO LTD
MIXED
Drug Impact Rating3/10
Trial phase
Approved (marketed)
Time to market
Already approved and commercially available since 2012 (US/EU).
Why 3/10
No scheduled binary catalyst (PDUFA, pivotal readout, or Advisory Committee) exists for this already-approved, marketed drug in the next 12 months, capping the impact score at 5; the drug accounts for roughly 3% of Takeda's total revenue, further limiting company-level share-price sensitivity.
Actionable Insight MIXED

With all US Orange Book patents and FDA exclusivity expired (May 2026), watch for generic teduglutide entrants that could erode Gattex/Revestive's roughly JPY 145 billion revenue base. Separately, Ironwood's once-weekly apraglutide has positive Phase 3 STARS data published in October 2026, while Lilly's $1.26B sonefpeglutide deal adds another long-acting competitor. Takeda's next quarterly update (likely January 2027) will show whether Gattex/Revestive revenue held or declined following the exclusivity loss.

Price Chart

Loading chart...

Executive Summary

Gattex (US) and Revestive (EU) are the brand names for teduglutide, a GLP-2 analog approved since 2012 for short bowel syndrome (SBS), first in adults and later expanded to children 1 year and older. Takeda generated roughly JPY 145.7 billion (about $975 million) from the drug in its FY2025, making it a meaningful but not dominant product (roughly 3% of Takeda's total revenue). The drug faces mounting headwinds: all US patents and FDA exclusivity expired by May 2026, opening the door for generic competition, while next-generation once-weekly GLP-2 analogs (Ironwood's apraglutide with positive Phase 3 data, and Lilly's Phase 2 sonefpeglutide licensed for up to $1.26 billion) threaten the daily-injection incumbent. Takeda's FY2026 guidance projects modest growth to 154 billion yen. For a non-medical investor, this is a mature orphan drug facing a patent cliff and competitive pipeline, with no imminent binary catalyst for Takeda shares.

How It Works

Teduglutide is a manufactured copy of a natural gut hormone called GLP-2. It stimulates the lining of the intestines to grow and work better, helping people with short bowel syndrome absorb more fluids and nutrients from what they eat and drink, reducing their dependence on intravenous (IV) nutrition.

Trial Status

The drug is fully approved and marketed. A global long-term safety registry (NCT identifier not specified) is ongoing for patients with SBS treated with teduglutide in routine clinical settings. The FDA label was updated in September 2025 to include pediatric patients 1 year and older. Ironwood's apraglutide (once-weekly GLP-2) completed its Phase 3 STARS trial with positive results published October 2026; it is not yet approved. Lilly's sonefpeglutide (Hanmi) is in Phase 2.

The Two-Sided Case

▲ Bull Case3
Teduglutide is the only approved pharmacotherapy for short bowel syndrome (SBS), a rare, life-altering condition with few alternatives, supporting durable orphan-drug pricing power.
The label now covers both adults and pediatric patients 1 year and older, expanding the addressable population, and Takeda's long-term safety registry continues to build real-world evidence.
Takeda guided FY2026 Gattex/Revestive revenue to 154 billion yen (roughly $1 billion), up 6% reported from FY2025, and first-half FY2026 results (published Oct 29, 2026) reiterated that outlook.
▼ Bear Case3
Exclusivity has expired: all FDA Orange Book patents and regulatory exclusivity for Gattex Kit lapsed by May 16, 2026, opening the door for generic teduglutide entrants that could dramatically cut Takeda's roughly JP 145.7 billion in annual revenue.
Competing once-weekly GLP-2 analogs threaten the daily-injection profile of teduglutide. Ironwood's apraglutide posted positive Phase 3 STARS results in October 2026, and Lilly paid up to $1.26 billion for Hanmi's long-acting GLP-2 sonefpeglutide (Phase 2).
Revenue is largely flat: Gattex/Revestive grew only 1% at constant exchange rates in FY2025, and Takeda's own FY2026 guidance of 154 billion yen implies just 1% CER growth.

Upcoming Catalysts

  • Generic teduglutide market entry (exclusivity expired May 2026; no generic has confirmed launch as of Takeda's 20-F filed June 2026, per the DataIntelo report)
  • Ironwood apraglutide regulatory filings (Phase 3 STARS data published October 2026; potential NDA/MAA submission timeline TBD)
  • Sonefpeglutide (Lilly/Hanmi) Phase 2 SBS data readout
  • Takeda Q3 FY2026 results (expected early 2027) with Gattex/Revestive revenue update

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report

Sources · 12

Hover a chip for the title
1 accessdata.fda.gov2 drugs.com3 ema.europa.eu4 dataintelo.com5 pharsight.greyb.com6 pharmaphorum.com7 news.gastro.org8 gattex.com9 takeda.com10 en.wikipedia.org11 fda.gov12 ironwoodpharma.com